Syndax Pharmaceuticals, Inc. (SNDX) is a commercial-stage oncology and hematology biotech whose two approved medicines — Revuforj (revumenib), a menin inhibitor for certain acute leukemias, and Niktimvo (axatilimab), for chronic graft-versus-host disease (cGVHD) — anchor its investment case. With shares volatile after a late-stage pipeline setback, the question of whether SNDX can reach a $41 stock price target rests on the commercial trajectory of those two franchises rather than the discontinued indication.
Nine individual targets inform the $41 average analyst price target: Citi ($57), BTIG ($56), Mizuho ($45), Stifel ($40), J.P. Morgan ($40), H.C. Wainwright ($38), Barclays ($37), UBS ($33), and Bank of America ($23). The arithmetic mean is $41, but the wide $23–$57 range signals genuine disagreement about how quickly the oncology franchise scales.
Bullish firms such as Citi and BTIG emphasize Revuforj's expansion into a larger relapsed/refractory acute myeloid leukemia (AML) population. Citi reiterated its $57 target after the October 2026 Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed its primary endpoint, arguing IPF was never in its model. H.C. Wainwright likewise kept its $38 target. In contrast, Bank of America lowered its target to $23 from $26, while maintaining Buy, seeing limited read-through but remaining focused on Revuforj share capture. No firm carries a Sell or Hold rating, so the dispersion reflects valuation and execution assumptions rather than disagreement over direction.
At the October 12, 2026 close of $16.55, reaching $41 requires a rise of roughly 148% — a very large move. From the depressed after-hours level near $14, the implied upside is even larger. The path hinges on converting label expansion into durable revenue growth. In November 2025 the FDA expanded Revuforj's approval to relapsed/refractory mNPM1-mutated AML, and analysts see the drug competing across relapsed/refractory, post-transplant, and frontline settings. Niktimvo's cGVHD franchise continues with combination trials in earlier lines of therapy, with data expected later in 2026 and in early 2028. Still, the company is unprofitable, with trailing twelve-month EPS (earnings per share) around negative $2.52, so valuation support must come from revenue scaling toward profitability.
Expanded Revuforj approval into mNPM1 AML enlarges the addressable market beyond KMT2A-rearranged disease. Product revenue is growing from a low base — consensus projected roughly $318 million in 2026 revenue, up about 26% year over year — and the Niktimvo cGVHD opportunity adds a second commercial pillar. Analysts' uniformly Buy/Overweight stance, combined with a supportive regulatory pathway and pipeline catalysts in earlier treatment lines, provides the fundamental case underpinning the higher targets.
The October 2026 IPF failure removed what bulls had called "upside optionality," sharpening focus on the two existing franchises. Revuforj carries a boxed warning for QT prolongation, which some analysts warn could temper prescribing. The company burns roughly $400 million annually in research, development, and selling costs against a still-modest revenue base, and short interest near 26% of float signals significant skepticism. Competition in AML, execution risk on launches, and any further safety or efficacy setback could compress the multiple that higher targets imply.
The stock trades within a 52-week range of roughly $12.99 to $25.59. The $13 area near the 52-week low and the recent after-hours trough near $13.80 are near-term support levels to watch, while the $25.59 prior high and the psychological $25 level mark the first major resistance zone before any move toward $41. The post-miss selloff pushed shares below the $18–$19 zone that had acted as recent support, leaving the technical structure weakened in the short term.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may use different models. Upcoming items to watch include the next quarterly report (expected around late October to early November 2026), Revuforj launch and prescription trends, cGVHD frontline trial data expected later in 2026 and in early 2028, any further label or safety updates, and analyst target revisions following the IPF decision.
For traders tracking names like SNDX, AI Daily Buy/Sell Signals from Tickeron applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. Explore how these signals can support your own market monitoring.
The $41 central target, a mean of nine analyst targets spanning $23 to $57, sits far above the recent share price and reflects an optimistic but not unanimous view of Syndax's oncology and cGVHD franchises. Reaching it would require a very large move — roughly 148% from the October 12 close — driven primarily by Revuforj label expansion and Niktimvo execution. The IPF discontinuation narrows the story, while the boxed warning, heavy spending, and high short interest present real obstacles. Investors should weigh the wide analyst dispersion, monitor revenue and prescription trends, and track upcoming cGVHD data rather than treating the $41 figure as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To SNDX | 1D Price Change % | ||
|---|---|---|---|---|
| SNDX | 100% | -0.75% | ||
| REPL - SNDX | 51% Loosely correlated | +2.63% | ||
| KURA - SNDX | 46% Loosely correlated | -1.00% | ||
| VCYT - SNDX | 45% Loosely correlated | +3.19% | ||
| SMMT - SNDX | 43% Loosely correlated | -1.62% | ||
| SANA - SNDX | 42% Loosely correlated | -0.42% | ||
More | ||||